Natural phosphodiester bond CpG-DNA that contains immunomodulatory CpG motifs (PO-DNA) upregulates the expression of proinflammatory cytokines and induces an Ag-driven Th1 response in a CG sequence-dependent manner in mice. In humans, only phosphorothioate backbone-modified CpG-DNA (PS-DNA) and not PO-DNA has immunomodulatory activity. In this study, we found that liposome-encapsulated PO-DNA upregulated the expression of human β-defensin-2 (hBD-2) and major histocompatibility class II molecules (HLA-DRA) in a CG sequence-dependent and liposome-dependent manner in human B cells. Of the three different liposomes, DOTAP has the unique ability to enhance the immunomodulatory activity of PO-DNA. In contrast, HLA-DRA and hBD-2 promoter activation can be induced by liposomeencapsulated PS-DNA in a CG sequence-independent manner, depending on the CpG-DNA species. Our observations demonstrate that, when encapsulated with a proper liposome in the immune system, natural PO-DNA has the potential to be a useful therapy for the regulation of the innate immune response. [BMB reports 2010; 43(4): 250-256]
INTRODUCTION
Various microbial products such as lipopolysaccharide (LPS), peptidoglycan, lipoteichoic acid and bacterial DNA have pathogen-associated molecular pattern (PAMP) signatures; they are known as polyclonal activators of rapid immune responses. The innate immune system expresses conserved pattern recognition receptors, such as Toll-like receptors (TLRs), to discriminate itself from the PAMP signatures of infectious agents (1, 2) .
A growing body of evidence demonstrates that the innate immune system can use TLR9 to recognize bacterial DNA as non-self. TLR9 recognizes bacterial DNA and synthetic oligodeoxynucleotides that contain unmethylated CpG dinucleotides in the context of particular base sequences (CpG-DNA) (3, 4) . Experimental evidence suggests that CpG-DNA plays a significant immunomodulatory role in B lymphocytes, macrophages, dendritic cells and natural killer cells (5) (6) (7) (8) . The application of CpG-DNA is known to preferentially induce a Th1 response with increased levels of proinflammatory cytokines (for example IL-6, IL-12, IFN-α and IFN-γ) (9) (10) (11) as well as the regulation of Th1/Th2 immune responses (4) . Moreover, CpG-DNA upregulates the expression of major histocompatibility (MHC) class II molecules and costimulatory molecules (CD40, CD80 and CD86) in the immune system (10, 12) . Recently, we reported that the expression of human β-defensin-2 (hBD-2) is upregulated in response to CpG-DNA in human B cells (13) . Therefore, CpG-DNA is considered a potentially useful therapeutic substance for immune adjuvants, allergic diseases and infectious diseases (4, 10) .
Several investigators have used phosphorothioate backbone-modified CpG-DNA (PS-DNA), in which sulfurs replace the nonbridging oxygen atoms in the backbone, to provide resistance to nuclease activity and to improve the efficiency of CpG-DNA uptake into cells (14) (15) (16) . PS-DNA has been used for clinical applications due to its ability to dramatically increase the activation of CpG-DNA-induced innate immunity (17) (18) (19) . However, several investigators have suggested that PS-DNA induces severe side effects, such as arthritis, transient splenomegaly, lymphoid follicle destruction, immunosuppression and PS-DNA-specific IgM production in PS-DNA-treated mice in a CG sequence-dependent and backbone modification-dependent manner (20) (21) (22) (23) . Thus, the identification of potent immunomodulatory CpG-DNA that does not severe side effects is required for inducing a well-controlled immune response.
To develop potent CpG-DNA without severe side effects, we identified natural phosphodiester bond CpG-DNA (PO-DNA) through a computer-assisted analysis and by screening the chromosomal DNA sequences of M. bovis having immunomodulatory activity (24) . Potent PO-DNA, specifically MB-ODN 4531(O) containing immunomodulatory CpG motifs, is an inducer of the innate immune response and a powerful adjuvant for the induction of Ag-driven Th1 responses without severe side effects, such as PS-DNA-specific IgM production and transient splenomegaly (23, 24) . However, the activity of PO-DNA with immunomodulatory activity in mice is relatively low in human cells (3) . Previously, it was reported that activation of innate immune responses in human cells could be induced by PO-DNA encapsulated in liposomes (25, 26) . In this study, we report that expression of hBD-2 and MHC class II molecule (HLA-DRA) is upregulated by liposome-encapsulated PO-DNA in a CG sequence-dependent and liposome-dependent manner in human B cells.
RESULTS AND DISCUSSION
Effect of liposome-encapsulated PO-DNA on HLA-DRA and hBD-2 promoter activation
Previously, we reported that PO-DNA upregulates the expression of proinflammatory cytokines (TNF-α and IL-12) and induces Ag-driven Th1 responses in a CG sequence-dependent manner in mice (23, 24) . In contrast to PS-DNA, the effects of PO-DNA are not evident in human cells (3) . (Fig. 3A, C) . These results suggest that liposome-encapsulated PO-DNA is capable of activating the human B cell line RPMI 8226 in a CG sequencedependent manner. Basal luciferase activity was also detected in cells treated with MB-ODN 4531(S)GC (Fig. 3B, D) . However, treatment with liposome-encapsulated CpG-DNA 2006 (S)GC led to activation of the HLA-DRA and hBD-2 promoter. This is comparable to activation by CpG-DNA 2006(S) (Fig.  3B, D) . Furthermore, luciferase activity was also detected in cells stimulated with liposome-encapsulated non-CpG-DNA 2041(S) and non-CpG-DNA 2041(S). These results show that, depending on the CpG-DNA species, HLA-DRA and hBD-2 promoter activation is induced by liposome-encapsulated PS-DNA in a CG sequence-independent manner.
Effect of liposome-encapsulated PO-DNA on
MyD88-mediated and NF-κB activation-mediated HLA-DRA and hBD-2 promoter activation
We examined the requirement for MyD88 in liposome-encapsulated PO-DNA-induced HLA-DRA and hBD-2 promoter activation. As shown in Fig. 4A , B, a dominant negative version of MyD88 (ΔMyD88) significantly reduces liposome-encapsulated PO-DNA-induced HLA-DRA and hBD-2 promoter activation. These results show that the signal transduction molecule MyD88 of the TLR/IL-1R signaling pathway is required for activation of the HLA-DRA and hBD-2 promoter in RPMI 8226 cells stimulated by liposome-encapsulated PO-DNA; the same requirement also exists for PS-DNA. To determine whether NF-κB activation is affected in liposome-encapsulated PO-DNA-induced HLA-DRA and hBD-2 promoter activation, we cotransfected an expression plasmid encoding mutant IκBα protein (IκBα Super Repressor, IκBα SR) into RPMI 8226 cells with the promoter-reporter construct. The induction of HLA-DRA and hBD-2 promoter activity was inhibited by the expression of IκBα SR in cells treated with liposome-encapsulated PO-DNA (Fig. 4) . These results confirm that both IκBα degradation and NF-κB activation are involved in liposome-encapsulated PO-DNA-induced HLA-DRA and hBD-2 promoter activation, similar to that of PS-DNA.
Although investigators mainly use PS-DNA for the clinical application of therapeutic CpG-DNA, the phosphorothioate backbone linkage reportedly induces CpG dinucleotide sequence-independent and backbone modification-dependent side effects (20) (21) (22) (23) . We therefore identified natural PO-DNA with immunomodulatory activity from bacterial chromosomal DNA. Immunomodulatory PO-DNA, named MB-ODN 4531(O), plays a functional role as a Th1-responsive adjuvant in mice (24, 27) . However, PO-DNA was much less potent in inducing HLA-DRA and hBD-2 promoter activation in RPMI 8226 cells than in mice (Fig. 1) .
The use of liposomes as vehicles for CpG-DNA delivery has been extensively evaluated for the purpose of developing therapeutic CpG-DNA (28, 29) . Encapsulated liposomes can increase the half-life of CpG-DNA and protect it from nuclease http://bmbreports.org BMB reports activates OVAspecific cytotoxic T lympocytes, which exhibit potent cytotoxicity against OVA-expressing tumors (32) . On the other hand, PO-DNA encapsulated in liposomes, especially DOTAP and Lipofectin, reportedly increases the expression of proinflammatory cytokines in human cells (25, 26) . However, there have been no precise analytical investigations into the relationship between liposome-encapsulated PO-DNA and immunomodulatory function in human immune cells. Our work demonstrates that PO-DNA encapsulated in DOTAP can elicit HLA-DRA and hBD-2 promoter activation and gene expression in RPMI 8226 cells in a CG sequence-dependent manner (Fig.  3A, C) . In contrast to PO-DNA, the promoter activities of HLA-DRA and hBD-2 are induced by liposome-encapsulated PS-DNA in a CG sequence-independent manner, though the extent of induction depends on the CpG-DNA species (Fig. 3B,  D) .
Recognition of CpG-DNA by TLR is known to induce the activation of the MyD88/IL-1R-associated kinase (IRAK) pathway (10) . Activation of the MyD88/IRAK pathway stimulates several transcription factors such as NF-κB for cytokine production. We directly demonstrated by promoter-reporter assay that NF-κB activation induces HLA-DRA and hBD-2 promoter activation in response to PO-DNA-encapsulated DOTAP stimulation. We also provide evidence that MyD88 is required for HLA-DRA and hBD-2 promoter activation in response to PO-DNA encapsulated in DOTAP (Fig. 4) .
In summary, our observations demonstrate that natural PO-DNA has potential as a useful therapy and as a regulator of the innate immune response when encapsulated in liposome in the human immune system. Of the three different liposomes, DOTAP is the most useful and unique in terms of enhancing immunomodulatory activity. Accordingly, further investigation and screening of other liposomes can be a strategy for developing more potent therapeutics.
MATERIALS AND METHODS

ODNs and reagents
ODNs were purchased from GenoTech (Daejeon, Korea). The CpG-DNA sequences used in this study were either phospho-http://bmbreports.org 
Cell culture
The human B cell line RPMI 8226 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in RPMI 1640 medium containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 100 U/mL of penicillin and 100 μg/mL of streptomycin. Viability was assayed by trypan blue dye exclusion.
Construction of luciferase reporter plasmids
The HLA-DRA promoter fragment −323 to +43 was amplified by PCR using human genomic DNA (Clontech, Palo Alto, CA, USA) as a template with the following primer sets (12): DRA (-323), 5'-GGTACCATCTGTATTTAGCTCT-3' and DRA(+43), 5'-AAGCTTGGGAGTGAGGCAGAACAGAC-3'. To construct a hBD-2 promoter-reporter plasmid containing −2,531 to +111 (13), we amplified an hBD-2 promoter fragment by PCR using human genomic DNA (Clontech) as a template with the following primer set: HDB (-2531), 5'-GGTACCAATTTCTTTGTC TCCAT-3' and HDB(+111), 5'-CTCGAGGCATCAGGAATATG A-3'. These fragments were then ligated into the luciferase reporter plasmid pGL3-Basic vector (Promega, Madison, WI, USA), which yielded the reporter constructs pHLA-DRA-Luc and phBD-2-Luc.
Transfection and luciferase assay
Transfection and the luciferase assay were performed as previously reported (33) . RPMI 8226 cells were placed into six-well plates one day before transfection. After transfection, the cells were placed in complete medium for 24 h and then treated with CpG-DNA or liposome-encapsulated CpG-DNA for 12 h. Cells were harvested, washed and lysed by freezethawing three times. Luciferase activities were determined by Dual-Luciferase Reporter Assay (Promega) using a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). To normalize individual assays, we adjusted transfection efficiency by cotransfecting the promoterless Renilla luciferase vector pRL-null (Promega).
RT-PCR analysis
After cells were treated with CpG-DNA or liposome-encapsulated CpG-DNA for the indicated time periods, total RNA was extracted using an RNeasy RNA isolation kit (Qiagen). Five micrograms of total RNA were reverse-transcribed in the firststrand synthesis buffer containing 6 μg/ml of oligo (dT) primer, 50 U of reverse transcriptase, 4 mM of dNTP, and 40 U of RNase inhibitor. We performed a standard PCR reaction for 25 cycles using a cDNA mixture as a template with the following primer sets: HLA-DRA, 5'-CGAGTTCTATCTGAATCCTG-3' (sense), 5'-GTTCTGCTGCATTGCTTTTGC-3' (anti-sense); Human BD-2, 5'-GGG TCT TGT ATC TCC TCT TC-3' (sense) and 5'-ATT TGG TTT ACA TGT CGC ACG-3' (anti-sense); human actin, 5'-GGGTCAGAAGGATTCCTATG-3' (sense), 5'-CCTTA ATGTCACGCACGATTT-3' (anti-sense). The PCR products were detected by UV light after being resolved on a 1% agarose gel.
Measurement of hBD-2
To measure the amount of hBD-2, we added CpG-DNA or liposome-encapsulated CpG-DNA to RPMI 8226 cells, followed by incubation at 37 o C with 5% CO2 for 24 h. The culture supernatants were collected and hBD-2 levels were measured using a commercially available ELISA kit for hBD-2 (Peprotech, Rocky Hill, NJ, USA) in accordance with the manufacturer's specifications.
